1. The role of HIF-1*α* pathway in cellular adaptation to hypoxic stress {#s0005}
========================================================================

Mammalian cells need to maintain proper oxygen hemostasis in order to execute their aerobic metabolism and energy generation. In cancer, heart diseases, or chronic obstructive pulmonary disorders, the cellular oxygen balance is highly impaired, and cells become hypoxic (having low oxygen (O~2~) levels)[@bib1]. Hypoxia is common in many types of solid tumors, where tumor cells proliferate rapidly and form large solid tumor masses, leading to obstruction and compression of the blood vessels surrounding these masses. These abnormal blood vessels often do not function properly and result in poor O~2~ supply to the center tumor regions[@bib2]. Tumor cells in this hypoxic region begin to adapt these low oxygen tension conditions by activating several survival pathways. Activation of HIF-1 transcription factor is the most recognized pathway adopted by hypoxic cells in this harsh microenvironment (reviewed in references[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]).

Activated HIF-1 plays a crucial role in adaptive responses of the tumor cells to changes in oxygen through transcriptional activation of over 100 downstream genes which regulate vital biological processes required for tumor survival and progression. Examples include genes involved in glucose metabolism, cell proliferation, migration and angiogenesis[@bib11] ([Fig. 1](#f0005){ref-type="fig"}). For example, in a rapidly growing tumor tissue, HIF-1 helps hypoxic tumor cells to shift glucose metabolism from the more efficient oxidative phosphorylation to the less efficient glycolytic pathway in order to maintain their energy production (the Warburg effect)[@bib12]. For this reason, hypoxic cells tend to consume more glucose in order to meet their energy needs. HIF-1 mediates this metabolic conversion through the induction of enzymes involved in the glycolysis pathway and overexpression of glucose transporters (GLUTs) which increase glucose import into tumor cells[@bib3]. Another example involves the HIF-1 transcriptional induction of several pro-angiogenic factors such as the vascular endothelial growth factor (VEGF), which in turn stimulates the development of new blood vessels to enrich tumor cells with oxygen for their growth[@bib13]. In addition, HIF-1 promotes tumor metastasis into distant and more oxygenated tissues through the transcriptional activation of oncogenic growth factors such as transforming growth factor beta3 (TGF-*β*3), epidermal growth factor (EGF) and others[@bib13], [@bib14]. Altogether, HIF-1 activation in tumor cells is one of the key masters orchestrating their adaptation mechanisms to the hypoxia environment.

2. Discovery of the HIF-1 protein {#s0010}
=================================

HIF-1 was initially discovered by Semenza and co-workers[@bib15] in 1991 during a study conducted on erythropoietin (*EPO*) gene, a gene responsible for encoding erythropoietin hormone for red blood cells production. Cis-acting DNA sequences (5′--RCGTG-3′) were identified in the 3′-flanking region of this EPO gene. These DNA sequences were found to be essential for the transcriptional activation of EPO gene in response to hypoxia and thus they were named as hypoxia response elements (HRE). Further studies discovered that the transcriptional activation of many regulatory genes is initiated through binding of a specific protein that is induced under hypoxia conditions to the HRE. Later this protein was identified as HIF-1[@bib16].

3. HIF-1 structure {#s0015}
==================

HIF-1 is a heterodimeric transcription factor, composed of two subunits, the HIF-1*α* (or its analogs HIF-2*α* and HIF-3*α*) and HIF-1*β* subunits[@bib17]. HIF-1*α* is an oxygen sensitive subunit and its expression is induced under hypoxic conditions. In contrast, HIF-1*β* is constitutively expressed. HIF-1*β* is also known as aryl hydrocarbon nuclear translocator (ARNT), because it was discovered before HIF-1*α* and was identified as a heterodimeric partner of aryl hydrocarbon receptor (AhR). HIF-1*β* binds to AhR facilitating its translocation to the nucleus[@bib17]. These two subunits belong to bHLH-PAS protein family, because their structures are related to two nuclear proteins found in *Drosophila* (Per and Sim, PAS) which have basic-helix-loop-helix (bHLH) motif[@bib18], [@bib19] ([Fig. 2](#f0010){ref-type="fig"}). The bHLH proteins are characterized by having recognizable domains (b, HLH, PAS and TAD) which can regulate their own transcriptions as well as expression of other family members. In general, the bHLH-PAS motifs are essential to allow heterodimer formation between HIF-1*α* and HIF-1*β* subunits and for binding to the HRE-DNA sequence on the target genes. Base domains were found to have DNA binding properties required for binding the HRE on the gene, while HLH motif is where dimerization with other proteins occurs. Interestingly, PAS was found to be the only domain which is conserved among all members of this protein family (HIF-1*α*, ARNT, AhR, and PAS) and not found in any other types of proteins.

The HIF-1*α* subunit has two transactivation domains (TAD): NH~2~-terminal (N-TAD) and COOH-terminal (C-TAD). These two domains are responsible for HIF-1*α* transcriptional activity[@bib20]. C-TAD interacts with co-activators such as CBP/p300 to modulate gene transcription of HIF-1*α* under hypoxia. N-TAD is responsible for stabilizing HIF-1*α* against degradation[@bib21]. Moreover, all HIF-*α* subunits are distinct from HIF-1*β* in that they all have an oxygen-dependent degradation domain (ODDD) overlapping N-TAD in their structures. This ODDD domain is important in mediating O~2~ regulation stability[@bib22] ([Fig. 2](#f0010){ref-type="fig"}).

Three closely related isoforms of HIF-*α* were known: HIF-1*α*, HIF-2*α*, and HIF-3*α*[@bib20], [@bib23]. Unlike HIF-3*α*, HIF-2*α* shows a noticeable degree of amino acid sequence similarity with HIF-1*α* (48% sequence similarity). This identity resemblance could explain their common capability of hetero-dimerization with HIF-1*β* and binding with HREs. Interestingly, HIF-1*α* and HIF-2*α* show different pattern of tissue distributions. HIF-1*α* is ubiquitously expressed in the body, but HIF-2*α* expression is stricter to specific tissues[@bib23]. HIF-3*α* was less known until the discovery of the inhibitory PAS (IPAS), a spliced variant of HIF-3*α*. This domain doesn׳t show any intrinsic transactivation activity in comparison to the C-TAD of HIF-1*α* and HIF-2*α*, and it is a dominant-negative regulator over HIF-1/DNA binding ability[@bib24].

4. Regulation of HIF-1*α* pathway {#s0020}
=================================

The activity and accumulation of HIF-1*α* protein were found to be regulated at different levels throughout its life cycle inside the cells. Independently from O~2~ levels, HIF-1*α* is constitutively transcribed and synthesized through a series of signaling events involving several growth factors and other signaling molecules[@bib25] ([Fig. 3](#f0015){ref-type="fig"}a). HIF-1*α* undergoes quick degradation under normoxic conditions and normally has a very short half-life (about 5 min)[@bib26]. In contrast, under hypoxic conditions, several pathways have been shown to control HIF-1*α* stability and transcriptional activity *via* post-transnational modifications involving hydroxylation, acetylation, ubiquitination, and phosphorylation reactions, as discussed below[@bib25].

4.1. Oxygen-dependent regulation of HIF-1α pathway 'hypoxic regulation' {#s0025}
-----------------------------------------------------------------------

### 4.1.1. pVHL-dependent pathway {#s0030}

Under normal oxygen tension, HIF-1*α* protein expression is negatively regulated by proteasomal degradation and ubiquitination in a pathway involving von Hippel−Lindau protein (pVHL), a tumor suppressor protein and one of the recognized components of an E3 ubiquitin protein ligase[@bib27]. The two proline residues (P^402^/ P^564^) located in the LXXLAP amino acid motif in the ODDD of HIF-1*α* were found to be good substrates for the action of a group of enzymes called prolyl-4-hydroxylases (PHDs) or HIF-1 prolyl hydroxylases (HPH)[@bib22], [@bib28]. These are 2-OG-dependent dioxygenases enzymes which require oxygen for their hydroxylation action, in addition to other co-factors such as iron and ascorbate. Hence, hydroxylation of proline residues by PHDs occurs only when there is sufficient amount of oxygen[@bib7], [@bib28] ([Fig. 3](#f0015){ref-type="fig"}b). Moreover, another residue in the ODDD (lysine, K^532^) could be acetylated by an enzyme called arrest-defective-1 (ARD-1), an acetyl transferase enzyme[@bib29] ([Fig. 3](#f0015){ref-type="fig"}b). Although ARD activity does not depend on oxygen availability, the expression of ARD is decreased under hypoxia[@bib29]. Consequently, modified HIF-1*α* subunits with hydroxylated P^402^/P^564^ and acetylated K^532^ moieties are preferably recognized by pVHL and are tagged for ubiquitination and proteasomal degradation[@bib30]. Since both the hydroxylation action from PHDs and ARD-1 expression require the presence of oxygen, under hypoxic condition, neither hydroxylation nor acetylation of HIF-1*α* proline and lysine residues occurs, resulting in stabilization of HIF-1*α* structure.

### 4.1.2. pVHL-independent pathway {#s0035}

Another oxygen-dependent major mechanism for negative regulation of HIF-1*α* pathway under normoxia is through controlling HIF-1*α* transactivation. This pathway represents another level of post-translational modifications of HIF-1*α* transactivation domain but does not involve the pVHL protein. The transcriptional activation of HIF-1*α* target genes is initiated through the cooperative binding of C-TAD in the HIF-1*α* and the co-activator CBP/p300. In normoxia, oxygen dependent hydroxylation of HIF-1*α* asparagine (N^803^) residue by factor inhibiting HIF-1 (FIH-1), also known as asparginyl hydroxylase, blocks the interaction between the two domains, abrogating the subsequent HIF-1*α* mediated gene transcription[@bib31], [@bib32], [@bib33], [@bib34] ([Fig. 3](#f0015){ref-type="fig"}c). Alternatively, hypoxia encourages this interaction through the inhibition of oxygen dependent hydroxylation of N^803^, resulting in transcriptional activation of the target genes[@bib32], [@bib33], [@bib34].

In summary, oxygen-dependent regulation of HIF-1*α* pathway involves a series of post-translational modifications. The pathway involving pVHL regulates HIF-1*α* stabilization, while that not involving VHL regulates HIF-1*α* transactivation.

4.2. Oxygen-independent oncogenic regulation of HIF-1α pathway {#s0040}
--------------------------------------------------------------

In addition to the major role of hydroxylases in regulating HIF-1*α* activity, there are pathways involving oncogenic activation that have considerable contributions in controlling HIF-1*α* protein levels. In non-hypoxic conditions, growth factors, cytokines and other signaling molecules tend to accumulate HIF-1*α* protein in cells.

### 4.2.1. Growth factor signaling pathways {#s0045}

Activation of phosphatidyl inositol-4,5-bisphosphate-3-kinase (PI3K) can upregulate the HIF-1*α* protein translation[@bib35], [@bib36], [@bib37]. PI3K regulates protein syntheses through its target protein kinase B (Akt) and downstream component mammalian target of rapamycin (mTOR). mTOR mediates its action *via* phosphorylation of the eukaryotic translation initiation factor 4E (eIF-4E) binding protein (4E-BP1) disrupting the integrity of these two components, which is essential for inhibiting cap-dependent mRNA translation, resulting in enhanced HIF-1*α* protein translation[@bib38] ([Fig. 3](#f0015){ref-type="fig"}a). Additionally, phosphorylation of p70 S6 kinase (S6K) by mTOR promotes the phosphorylation of its substrate, the ribosomal protein S6, and induces protein translation[@bib38] ([Fig. 3](#f0015){ref-type="fig"}a). This pathway is antagonized by the tumor suppressor protein (PTEN) which reverses the phosphorylation of PI3K products[@bib38].

Certain growth factors activate RAS which in turn stimulates RAS/RAF/MEK/ERK kinase cascade[@bib36] ([Fig. 3](#f0015){ref-type="fig"}a). Activated ERK phosphorylates 4E-BP1, S6K, and MAP kinase interacting kinase (MNK). MNK can also phosphorylate eIF-4E directly[@bib39]. The net result of these signaling events is the increased rate of mRNA translation into HIF-1*α* protein. Interestingly, ERK is not only involved in regulation of HIF-1*α* synthesis but also its transcriptional activation. ERK phosphorylates the co-activator CBP/p300 so it increases HIF-1*α*/p300 complex formation, and thus stimulats its transcriptional activation function[@bib39] ([Fig. 3](#f0015){ref-type="fig"}c).

### 4.2.2. Mdm2 pathway {#s0050}

It was observed that loss of p53 tumor suppressor gene in certain types of tumors is associated with elevated levels of HIF-1*α*[@bib40]. This could be explained that in normoxia conditions, HIF-1*α* binds to the p53 and allows Mdm2 (mouse double minute 2 homolog) mediated ubiquitination and proteasomal degradation of HIF-1*α*[@bib41] ([Fig. 3](#f0015){ref-type="fig"}d). In hypoxic tumors, loss or mutations in tumor suppressor genes revokes any chances for Mdm2-mediated degradation of HIF-1*α*.

### 4.2.3. Heat shock protein 90 (Hsp90) {#s0055}

It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1*α* levels regardless of the availability of oxygen[@bib42]. Hsp90 is known to bind directly with HIF-1*α* inducing some conformational changes in its structure to fit and couple with HIF-1*β* initiating its transactivation[@bib43] ([Fig. 3](#f0015){ref-type="fig"}e). In addition, Hsp90 can stabilize HIF-1*α* against its non-VHL dependent degradation.

5. Targeting HIF-1*α* pathway for cancer therapy {#s0060}
================================================

Considering the multiple roles of HIF-1 in tumor progression and metastasis, there have been great interests in developing inhibitors targeting this pathway. It is clear that HIF-1*α* regulation pathway is a highly complex network involving several signaling cascades and overlapping mechanisms, each of which could serve as a promising target or step to intervene selectively. It is not surprising that most of the reported HIF-1*α* inhibitors were originally discovered for targeting other endogenous molecules and later their HIF-1*α* inhibitory activity was recognized through some empirical testing. For this reason, there are no specific HIF-1*α* inhibitors currently and developing specific HIF-1*α* inhibitors in hypoxic tumors represent a challenge.

The searching process for novel HIF-1*α* inhibitors usually starts with chemical libraries screening as a preliminary step to identify novel molecules convenient for HIF-1*α* inhibition testing. Following this step, cell-based high throughput screens (HTS) are employed to test the identified compounds for their HIF-1*α* inhibitory action[@bib44]. Cell-based HTS depends on measuring the level of HIF-1*α* induced in mammalian cells in response to hypoxia conditions (1% O~2~) or hypoxia activators, such as deferoxamine (DFO) and cobalt chloride (CoCl~2~). Stably transfected mammalian cell lines with constructs containing multiple copies of HRE that drives transcription of a reporter gene (luciferase (Luc) reporter gene is the most commonly used one) have been widely used for testing HIF-1*α* inhibition. HIF-1*α* inhibition can usually be achieved through modulation of one of the following steps: HIF-1*α* mRNA expression; HIF-1*α* protein level (protein translation or degradation); HIF-1*α*/HIF-1*β* dimerization; HIF-1*α*-DNA binding (HIF-1*α*/HRE); or HIF-1*α* transcriptional activity (CH-1 of p300/ C-TAD of HIF-1*α*).

To define which level within HIF-1*α* pathway is targeted by the identified hit in HTS, Melillo[@bib44] described a simple algorithm for validation purposes. This algorithm involves several consequential steps of either cell-based or cell-free assays to consider certain level while ruling out others involved in HIF-1*α* regulation to precisely dissect the mechanism of action of the tested inhibitor[@bib44] ([Fig. 4](#f0020){ref-type="fig"}).

The first step of this validation scheme is to test the effect of the HIF-1*α* inhibitor on the hypoxic induction of mRNA expression of HIF-1 target genes, such as *VEGF*, *GLUT1*, or *EPO* by reverse transcription polymerase chain reaction (RT-PCR) or enzyme-linked immunosorbent assay (ELISA) method[@bib45]. If the tested inhibitor showed negative induction effect on the target gene, Western blotting should be the following step to measure the HIF-1*α* protein levels in tumor cells cultured under hypoxia or in the presence of hypoxia mimics (DFO, CoCl~2~)[@bib46]. In case the tested compound impaired the hypoxic induction of HIF-1*α* protein, the expected mechanism of action would be either hindering HIF-1*α* protein translation or increasing its degradation. To specify the involvement of protein translation or degradation, experiments can be conducted in the presence of proteasomal inhibitors, such as PS-341 or MG-132[@bib47]. In addition, pulse-chain experiments are employed for assessment of *de novo* HIF-1*α* protein synthesis. The effect of the tested compound on HIF-1*α* mRNA expression should be excluded by evaluating its level[@bib48]. If an inhibitor does not negate hypoxic induction of HIF-1*α* protein, the other mechanisms (DNA binding, protein dimerization, or transcriptional activity) should be considered for further investigation. ELISA, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP experiments) are used to test for the inhibition of HIF-1/DNA binding[@bib49]. Immunoprecipitation experiments are commonly conducted to detect the inhibition of HIF-1*α*/HIF-1*β* dimerization[@bib50]. Unequivocally, the final step in this algorithm would be testing the inhibition of HIF-1*α* transcriptional activity through testing the interaction between the CH-1 domain of p300 and the C-TAD of HIF-1*α* peptides in a cell-free binding assay[@bib51]. [Fig. 4](#f0020){ref-type="fig"} illustrates these steps.

6. Molecules intervening the HIF-1*α* pathway {#s0065}
=============================================

There are many small molecules reported as HIF-1*α* inhibitors in literature. We categorize them in this review based on their targets, structures and putative mechanisms of action ([Figure 5](#f0025){ref-type="fig"}, [Figure 6](#f0030){ref-type="fig"}, [Figure 7](#f0035){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}).

6.1. Inhibitors of HIF-1α mRNA expression {#s0070}
-----------------------------------------

*EZN-2698* (**1**) is an anti-sense oligonucleotide, an RNA antagonist which specifically binds and inhibits the expression of HIF-1*α* mRNA as well as HIF-1*α* target genes. It was reported that inhibition of HIF-1*α* by EZN-2698 attenuates HIF-1*α* protein level and tumor progression in various *in vitro* (human prostate and glioblastoma cell lines) and *in vivo* studies[@bib52]. Phase I clinical trials revealed that EZN-2698 is a potential agent in patients with advanced renal cell carcinoma (RCC).

*Aminoflavone* (*AF*) (**2**) is another agent that inhibits HIF-1*α* mRNA expression. Although it is known as an AhR ligand, its exact mechanism of action as an inhibitor of HIF-1*α* mRNA expression is still unclear[@bib53].

6.2. Inhibitors of HIF-1α translation {#s0075}
-------------------------------------

Although the nature of the regulating HIF-1*α* protein translation is still poorly understood, several agents have been progressed that target the rate of HIF-1*α* protein synthesis, including but not limited to inhibitors of topoisomerase I and II, receptor tyrosine kinase, cyclin-dependent kinase, oncogenic pathways, and microtubule disrupting agents. However, the selectivity of these agents and the contribution of HIF-1*α* inhibition to their activities have not been fully established.

*Camptothecins* (*CPTs*, **3**) *analogues*, which have topoisomerase I (Top I) inhibitory activity, can inhibit HIF-1*α* protein accumulation in hypoxic U251 human glioma cells. CPTs poison Top 1 by inducing the formation of stable Top 1-DNA cleavage complexes generating double strands DNA breaks[@bib48]. Among the CPTs is topotecan (Hycamtin^®^--TPT, **3a**) which was originally discovered at the national cancer institute (NCI) in an HTS using a cell-based assay of HIF-1 transcriptional activity[@bib45]. Though TPT proved to be effective as antitumor agent in xenograft models[@bib54], its short half-life motivated the synthesis of other analogues with more favorable pharmacokinetic profiles. EZN-2208 (**3b**) is a TPT- congener, its high lipid solubility as a PEGylated analog of SN38 (**3c**), the active metabolite of irinotecan (Camptosar^®^--CPT-11, **3d**)[@bib55], have improved its pharmacokinetic and antitumor properties in preclinical models of solid tumors and lymphomas[@bib56]. A few phase I and II clinical trials have been conducted to provide evidence as for the anticancer activity of this agent.

*mTOR Inhibitors* (**4**) can also inhibit HIF-1*α* translation. The growth factor signaling pathway involving the downstream kinases PI3K/Akt/mTOR represents a major route of HIF-1*α* translation in over 70% of human cancer cell lines[@bib8]. Temsirolimus (Torisel^®^--CCI-779, **4**), and its counterparts, everolimus or rad001 (Afinitor^®^, **4a**) and sirolimus (Rapamycin^®^, **4b**) are mTOR inhibitors currently in clinical development for the treatment of solid tumors[@bib57]. Although mTOR and the overall process of HIF-1*α* protein synthesis are limited under normoxia, it was found that 75% of sporadic clear cell RCCs are VHL-deficient, thus, in this case HIF-1*α* translation can proceed smoothly serving as a target for mTOR inhibitors intervention[@bib58]. Temsirolimus and everolimus have passed phase III clinical trials and FDA approval successfully for treatment of metastatic RRC[@bib59]. Besides being mTOR inhibitor, temsirolimus was investigated in clinical development for treatment of breast cancer owing to its antiangiogenic activity[@bib60]. Among all inhibitors of the PI3K/AKT/mTOR pathway, only temsirolimus have gained such success.

*PI3K inhibitors LY294002* (**5**) *and wortmannin* (**6**) have been recognized for their anti-HIF activity. High levels of PI3K have been recognized as a common feature of solid tumors, and it is up-regulated by either a gain of function in PI3K itself or in its downstream target Akt. As PI3K-specific inhibitors, LY294002 (**5**) and wortmannin (**6**) limited the synthesis of HIF-1*α* protein in the prostate carcinoma-derived cell lines PC-3 and DU145 in a dose-dependent fashion[@bib35].

*Cardiac glycosides* (**7**) \[digoxin (**7a**), Ouabain (**7b**), and proscillaridin (**7c**)\] have been used for the treatment of congestive heart failure for decades. Interestingly, these drugs were identified as inhibitors of HIF-1*α* protein translation and HIF-2*α* mRNA expression in a cell-based screen of a library of drugs in clinical trials. Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts. These findings imply the involvement of the HIF-1 in the antitumor activity of digoxin[@bib60].

2-*Methoxyestradiol* (2ME2, **8a**), *the natural metabolite and its synthetic analogues* \[ENMD-1198 (**8b**), ENMD-1200 (**8c**), and ENMD-1237 (**8d**)\] have been recently recognized as antitumor and antiangiogenic agents in several clinical trials. Mechanistically, these agents bind to the colchicine binding site of tubulin and disrupt tumor interphase microtubules (MTs) which are required for HIF-1*α* down-regulation. It is worth mentioning that all of these compounds have shown favorable oral bioavailability, metabolic stability and safety profiles[@bib61], [@bib62]. The promising clinical benefits of cancer treatment with this line of agents will no doubt spur in research to more improved anti-tubulin drugs.

6.3. Inhibitors of HIF-1α stabilization {#s0080}
---------------------------------------

### 6.3.1. Hsp90 inhibitors {#s0085}

The binding of HSP90 to HIF-1*α* promotes HIF-1*α* activity in two ways: (1) it blocks the VHL-independent proteasomal degradation; and (2) it helps HIF-1*α* heterodimers acquire the appropriate conformation to recruit p300 and consequently initiate HIF-1 transactivation[@bib63]. Therefore, Hsp90 antagonists are expected to induce HIF-1*α* degradation.

*Geldanamycins* (GAs, **9**) are Hsp90 inhibitors. The natural benzoquinone ansamycin antibiotic "geldanamycin" (**9a**) was the first discovered Hsp90 inhibitor. It disrupts Hsp90 binding to client proteins by competing with its ATP binding site, exposing them to ubiquitination and proteasomal degradation. Geldanamycin semi-synthetic derivatives, 17-demethoxygeldanamycin (17-AAG, **9b**) or tanespimycin, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, **9c**) or alvespimycin hydrochloride, IPI-504 or retaspimycin, and 17-AG (IPI-493, **9d**), the major metabolite of 17-AAG and IPI-504, have progressed successfully through clinical trials for further clinical development by different pharmaceuticals[@bib64]. However, specificity of the antitumor activities of this group of agents should be addressed, given the fact that wide range of client proteins, not only HIF-1*α* may be affected by Hsp90 inhibition.

*Radicicols* (**10**) are another chemical class of Hsp90 inhibitors possessing different and overlapping mechanisms for HIF-1*α* inhibition. For example, radicicol (**10a**) prevents the interaction between HIF-1*α*/HIF-1*β* heterodimers and DNA attenuating the HIF-1 activation process without significant change in HIF-1*α* protein stability[@bib63]. KF58333 (**10b**) down-regulates the HIF-1*α* and VEGF post-transcriptional expression in different human cancers[@bib65].

*SCH66336* (**11**), a farnesyltransferase derivative demonstrating antitumor activity against non-small-cell lung cancer, inhibits the interaction between HIF-1*α* and Hsp90 promoting HIF-1*α* proteasomal degradation[@bib66].

*Apigenin* (**12**) is an antiangiogenic natural flavone. It was reported to block hypoxia-induced up-regulation of HIF-1*α*, GLUT-1, and VEGF proteins *via* degradation of HIF-1*α* through interference with the function of Hsp90[@bib67], [@bib68].

### 6.3.2. Histone deacetylase (HDAC) inhibitors {#s0090}

Recent evidence indicates that HIF-1*α* acetylation by p300/CBP associated factor (PCAF) at K^674^ in an environment of low NAD^+^ is critical for promoting p300 recruitment and subsequent expression of HIF-1*α* target genes. Sirtuin 1 (SIRT 1), a redox-sensing deacetylase considered as class III histone deacetylase (HDAC), opposes this reaction by catalyzing HIF-1*α* deacetylation at high NAD^+^ levels. However, when hypoxia is induced, the NAD^+^/NADH levels increase due to glycolysis down-regulating SIRT-1 favoring HIF-1*α* activation[@bib69]. The exact mechanism of HDAC inhibitors as HIF-1*α* inhibitors is still unclear, but they are known to antagonize the HIF-1*α* transactivation while upregulating ubiquitin-independent degradation pathways.

*Romidepsin* (**13**) *and trichostatin* (**14**) are known HDAC inhibitors. Romidepsin (Istodax^®^--FK228-FR901228, **13**) is an anticancer agent isolated from the bacterium *Chromobacterium violaceum* that was first reported by Fujisawa Pharmaceutical Company (now Astellas Pharma) in 1994[@bib70]. Romidepsin is a prodrug with disulphide bond which undergoes reduction in cells by cellular reducing activity involving glutathione releasing a zinc-binding thiol. This thiol blocks class I HDACs activity through reversible interaction with a zinc atom in the binding pocket of Zn-dependent histone deacetylases. The glutathione-mediated activation also implicates its clinical usefulness for counteracting glutathione-mediated drug resistance in chemotherapy[@bib71]. Romidepsin along with trichostatin (**14**), an antifungal antibiotic, are antiangiogenic HDAC inhibitors currently evaluated in clinical trials against a number of solid tumors[@bib72].

*LW6* (**15**) decreases HIF-1*α* protein expression through potentiating VHL expression, which in turn interacts with prolyl-hydroxylated HIF-1*α* for proteasomal degradation. This is demonstrated by its antitumor activity in mice xenografts of human colon cancer HCT116 cells. LW6 is thought to upregulate VHL expression *via* different proposed mechanisms including demethylation of the VHL promoter, inhibition of HDAC, or suppression of VHL proteasomal degradation[@bib73].

6.4. Inhibitors of HIF-1 dimerization {#s0095}
-------------------------------------

*Acriflavin* **(16)** is a mixture of 3,6-diamino-10-methylacridinium chloride (trypaflavin) and 3,6-diaminoacridine (proflavine), which was recently identified as HIF-1*α* inhibitor in cell-based screening assays. Acriflavin inhibits HIF-1 dimerization by binding to the PAS-B subdomain of HIF-1*α* and HIF-2*α*. Its promising safety profile and characteristic ability of binding to both HIF-1*α* and HIF-2*α* subunits might distinguish it as a candidate for clinical evaluation especially in cancer subtypes where increased levels of HIF-1*α* and HIF-2*α* are the main cause of tumor progress[@bib74].

6.5. Inhibitors of HIF-1/DNA binding {#s0100}
------------------------------------

*Echinomycin* (*quinomycin* A-NSC 526417, **17**), a natural cyclic peptide belonging to quinoxaline antibiotic family, was previously identified in a HIF-1-targeted cell-based HTS at the NCI using 140,000 small-molecule library. It binds specifically to the core of the HIF-1 recognition sequence 5′--CGTG-3′ in a sequence-dependent fashion precluding HIF-1 and DNA binding. Although immunoprecipitation experiments proved its ability to selectively inhibit HIF-1/DNA binding, the cytotoxicity encountered during several phase I and II clinical trials limited further clinical evaluation of this agent[@bib49].

*Anthracyclines* (**18**), the potent well-known chemotherapeutic agents, also act as HIF-1*α* inhibitors. To determine the molecular basis for their HIF-1 inhibitory action, several mechanistic studies were conducted and demonstrated that anthracyclines; doxorubicin (DXR, **18a**), danurubicin (DNR, **18b**), epirubicin (EPI), and idarubicin (IDA) disrupt the binding of HIF-1 to DNA in hypoxic human cells. This is attributed to their ability to intercalate DNA and induce topoisomerase II-mediated strand breaks[@bib75]. Moreover, administration of DXR or DNR to mice bearing human prostate cancer xenografts significantly inhibited tumor growth and vascularization, along with a decrease of circulating angiogenic cells (CAC). These findings imply that anthracyclines inhibition of HIF-1 activity reduced the expression of target genes (*e.g*., VEGF) responsible for tumor vascularization and growth. For this reason, these two agents attracted considerable interest for further preclinical studies to challenge the current paradigm available for treatment of prostate cancer which is characterized by elevated levels of HIF-1 protein[@bib76].

6.6. Inhibitors of HIF-1 transcriptional activity {#s0105}
-------------------------------------------------

Interruption of HIF-1*α* and HIF-1*β* binding to the co-factor p300 to form an active transcription complex, the final step towards HIF-1 transactivation, represents a potential mechanism by which small molecules may inhibit HIF-1 activity.

*Chetomin* (**19**), the antimicrobial dithioketopiperazine fungal metabolite, was identified as a small molecule blocking the transcriptional co-activation of HIF-1 pathway in 2004. Chetomin binds to and disrupts the tertiary structure of the CH1 domain of the co-activator p300, which hinders its interaction with HIF-1 and results in diminished HIF-1 transactivation[@bib51]. While local toxicity of chetomin restricted its further development, an interesting study was carried out and demonstrated that chetomin HIF-1 inhibition attenuates the expression of HIF-1 target genes and enhances the radiotherapy efficacy in human HT 1080 cells[@bib77]. Chetomin is one of many compounds indirectly affecting HIF-1*α* activity that showed great promise but has failed to exhibit safety in preclinical models.

*Bortezomib* (*Velcade*^®^--PS-341, **20**), a proteasome inhibitor, inhibits p300-HIF-1*α* binding at nanomolar concentrations. Paradoxically, at higher concentrations, it increases the level of HIF-1*α* protein by blocking its proteasomal degradation. At the molecular level, bortezomib stimulates the interaction between C-TAD of HIF-1 and FIH target site (Asn^803^); thereby enhancing FIH-mediated repression of p300 recruitment. Bortezomib is FDA approved for the treatment of relapsed and refractory multiple myeloma more than 10 years ago[@bib78]. More recently, the ability of bortezomib to downregulate the PI3K/AKT/mTOR pathway which is upstream of the HIF-1 pathway was demonstrated in prostate cancer cells[@bib79]. Based on this discovery, recent studies were designed to assess the anticancer spectrum of bortezomib as sole agent or adjuvant therapy for the treatment of different types of cancers[@bib80], [@bib81], [@bib82].

6.7. Inhibitors of HIF-1α at multiple levels {#s0110}
--------------------------------------------

*YC-1* (**21**) is an antiplatelet aggregation agent. It was originally discovered as an activator of platelet guanylate cyclase[@bib83] and later it was found to have HIF-1 inhibitory activity. YC-1 can enhance FIH binding to HIF-*α* CAD, which in turn dissociates the binding of the later to p300 co-activator and lead to the functional repression of HIF-1. This mechanism does not involve the FIH active site, Asn803[@bib84]. YC-1 can also impair HIF-1*α* and HIF-2*α* protein accumulation in a dose-dependent manner[@bib85]. In addition, YC-1 inhibited HIF-1*α via* the FIH-dependent CAD inactivation as well as *via* the protein down-regulation in HT1080 and H1299 cancer cell lines[@bib84]. Literature also revealed the anti-proliferative effect of YC-1 on cancer cells by arresting the cell cycle and promoting cell apoptosis[@bib86].

*PX-478* (**22**) is a melphalan derivative which has potent antitumor activity. It was suggested that PX-478 lowers HIF-1*α* levels by affecting multiple levels in the HIF-1*α* pathway: (1) inhibition of HIF-1*α* deubiquitination *via* p53 and pVHL independent mechanism, resulting in increased levels of polyubiquitinated HIF-1*α*; (2) reduction of HIF-1*α* mRNA expression; and (3) inhibition of HIF-1*α* translation. In this regard, PX-478 was reported active in a panel of cell lines with prominent selectivity towards inhibition of HIF-1*α* protein translation[@bib87].

7. Conclusions {#s0115}
==============

Hypoxia is a prominent micro-environmental feature in many types of solid tumors due to inadequate vascularization. It accounts for developing both radiotherapy and chemotherapy resistance. Tumor cells respond to changes in oxygen *via* delegating the transcriptional factor HIF-1*α* for orchestrating vast number of its essential cellular functions. Considering the profound impacts of HIF-1*α* on cancer progression *via* gene expression and the unsatisfactory efficacy of chemotherapy, there has been enormous growing interest in the biology of HIF-1*α* pathway and the development of direct or indirect HIF-1 inhibitors. The identification of novel HIF-1 inhibitors involves panels of cell-based or cell-free screens and assays, but the complexity involved in the regulation of the HIF-1*α* pathway has made the process of rational design of HIF-1*α* inhibitors very challenging. To date, no selective HIF-1*α* inhibitor has been clinically approved, partially due to the requirements of targeting protein-protein interactions without affecting other pathways. Nevertheless, there have been several approved drugs that indirectly affect the HIF-1*α* pathway and could serve as adjuvant therapy for certain types of cancers along with the existing treatments. Future directions would be directed towards developing drugs that are more specific for HIF-1 inhibition by better understanding of the molecular structure of domains that mediate critical functions of HIF-1. With the rapid advancement of molecular biology and emerging strategies in efficiently disrupting protein-protein interactions, it is very promising that selective HIF-1 inhibitors can be developed in the future.
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![Representative HIF-1*α* regulatory genes and their effects on cancer progression. LEP, leptin; NOS, nitric oxide synthase; VEGF, vascular endothelial growth factor; LRP1, LDL-receptor-related protein 1; ADM, adrenomedullin; TGF-*β*3, transforming growth factor-*β*3; EPO, erythropoietin; HK1, hexokinase 1; HK2, hexokinase 2; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; LDHA, lactate dehydrogenase; PKM, pyruvate kinase M; IGF2, insulin-like growth factor 2; IGF-BP2, IGF-factor-binding protein 2; IGF-BP3, IGF-factor-binding protein 3; TGF-*α*, transforming growth factor *α*; C-MYC, myelocytomatosis virus oncogene cellular homolog; ID2, DNA-binding protein inhibitor[@bib7].](gr1){#f0005}

![Functional domains (bHLH, PAS, TAD) for proteins related to bHLH-PAS family. HIF-1*α* and HIF-2*α* share high degree of amino acid sequence similarities and both of them have two distinct TADs (C-TAD and N-TAD). In contrast, HIF-3*α* only has N-TAD.](gr2){#f0010}

![Regulation of HIF-1*α* pathway at different levels. (a) Growth factors related pathways; (b) pVHL related pathways; (c) FIH-1 pathway; (d) Mdm2-p53 mediated ubiquitination and proteasomal degradation pathway; (e) Hsp90. Ras/Raf/MEK: Rat sarcoma/rapidly accelerated fibrosarcoma/MAPK/ERK kinase. These pathways regulate HIF-1*α* activity by regulating HIF-1*α* synthesis (a), HIF-1*α* stability (b, d, e), or HIF-1*α* transactivation (e, c).](gr3){#f0015}

![Schematic illustration of approaches adopted for discovery of HIF-1*α* inhibitors and investigation of their underlying inhibitory mechanisms of action (MOAs).](gr4){#f0020}

![HIF-1*α* inhibitors modulate different levels of the HIF-1*α* activation pathway.](gr5){#f0025}

![Chemical structures of molecules inhibiting HIF-1*α* pathway. Topotecan (**3a**): R~1~=OH, R~2~=CH~2~N(CH~3~)~2~, R~3~=H, R~4~=H; EZN-2208 (**3b**): R~1~=OH, R~2~=H, R~3~=CH~2~-CH~3~, R~4~=CO=CH~2~NHCOCH~2~O-(40k 4-arm-PEG); SN38 (**3c**)**:** R~1~= OH, R~2~= H, R~3~= CH~2~CH~3~, R~4~=H; Everolimus (**4a**): R~1~=CH~2~CH~2~OH; Sirolimus (**4b**): R=OCH~3~; 2ME2 (**8a**): R~1~=OH, single bond, R~2~=OH; ENDM-1198 (**8b**): R~1~=CONH2, double bond, R~2~=H; ENMD-1200 (**8c**): R~1~=CONH~2~, single bond, R~2~==CH~2~; ENMD-1237 (**8d**): R~1~=CONH~2~, single bond, R~2~=H; GA (**9a**): R=OCH~3~; 17-AAG (**9b**): R=**--**CH~2~NHCH~2~CH=CH~2~; 17AG (**9c**): R=NH~2~; 17-DMAG (**9d**): R=--CH~2~NH(CH~2~)~2~N(CH~3~)~2~.](gr6){#f0030}

![Chemical structures of molecules inhibiting HIF-1*α* pathway. Doxorubicin (**18a**): R=CH~2~OH; Danuorubicin (**18b**): R=CH~3~.](gr7){#f0035}

###### 

Classification of molecules intervening HIF-1*α* pathway according to their putative mechanisms of action.

  Mechanism of inhibition                                                     Inhibitor                               Target                                                                          
  --------------------------------------------------------------------------- --------------------------------------- ---------------------------------------- -------------------------------------- -------
  HIF-1*α* mRNA expression                                                    EZN-2698 (**1**)                        HIF-1*α* mRNA                                                                   
  Aminoflavone (**2**)                                                                                                                                                                                
  HIF-1*α* translation                                                        *CPTs* (**3**):                         Topoisomerase I                                                                 
  topotecan (**3a**), EZN-2208 (**3b**), SN38 (**3c**), irinotecan (**3d**)                                                                                                                           
  Temsirolimus (**4**)                                                        mTOR                                                                                                                    
  Everolimus (**4a**)                                                                                                                                                                                 
  Sirolimus (**4b**)                                                                                                                                                                                  
  LY294002 (**5**)                                                            PI3K                                                                                                                    
  Wortmannin (**6**)                                                                                                                                                                                  
  *Cardiac glycosides* (**7**):                                               HIF-1*α* protein/HIF-2*α* mRNA                                                                                          
  digoxin (**7a**), ouabain (**7b**), proscillaridin (**7c**)                                                                                                                                         
  *2ME2's* (**8**):                                                           Microtubules                                                                                                            
  2ME2 (**8a**), ENDM-1198 (**8b**), ENMD-1200 (**8c**), ENMD-1237 (**8d**)                                                                                                                           
  HIF-1*α* stabilization                                                      *GAs* (**9**):                          Radicicol (**10a**), KF58333 (**10b**)   SCH66336 (**11**), Apigenin (**12**)   Hsp90
  GA (**9a**),                                                                                                                                                                                        
  17-AAG (**9b**),                                                                                                                                                                                    
  17AG (**9c**),                                                                                                                                                                                      
  17-DMAG (**9d**)                                                                                                                                                                                    
  Romidepsin (KF228) (**13**)                                                 HDAC                                                                                                                    
  Trichostatin (**14**)                                                                                                                                                                               
  LW6 (**15**)                                                                HDAC/VHL                                                                                                                
  HIF-1*α* dimerization                                                       Acriflavin (**16**)                     PAS-B                                                                           
  HIF-1/DNA binding                                                           Echinomycin (**17**)                    5′-CGTG-3′                                                                      
  *Anthracyclines* (**18**): doxorubicin(**18a**), danuorubicin(**18b**)      HRE                                                                                                                     
  HIF-1 transcriptional activity                                              Chetomin (**19**)                       CH1 domain of p300                                                              
  Bortezomib (**20**)                                                         C-TAD of HIF-1*α* and Asn^803^ of FIH                                                                                   
  HIF-1*α* at multiple levels                                                 YC-1 (**21**)                           HIF-1&2 protein/FIH                                                             
  PX-478 (**22**)                                                             HIF-1&2 protein                                                                                                         
